Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Rocket Pharmaceuticals, a leader in genetic therapies for rare disorders, announced participation in two key events: the 22nd Annual Needham Virtual Healthcare Conference and Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit.

The Needham Conference is scheduled for April 18, 2023, at 8:45 a.m. ET, while the Chardan Summit will take place on April 25, 2023, at 9:00 a.m. ET. Both presentations will be accessible via a webcast on the company’s investor website.

Rocket’s pipeline includes therapies for conditions like Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Danon Disease, demonstrating its commitment to addressing high unmet medical needs.

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Company management will participate in the 22nd Annual Needham Virtual Healthcare Conference and Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. Participation details are as follows:

22nd Annual Needham Virtual Healthcare Conference
Fireside Chat Presentation
Date: April 18, 2023
Time: 8:45 a.m. ET

Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Fireside Chat Presentation
Date: April 25, 2023
Time: 9:00 a.m. ET

A webcast of both events will be available under “Events” in the Investors section of the Company’s website at https://ir.rocketpharma.com/.

About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. The Company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LV) based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. Rocket also has preclinical AAV-based gene therapy programs in PKP2-arrhythmogenic cardiomyopathy (ACM) and BAG3-associated dilated cardiomyopathy (DCM). For more information about Rocket, please visit www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking Statements
Various statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, the expected timing and outcome of Rocket’s regulatory interactions and planned submissions, Rocket’s plans for the advancement of its Danon Disease program, including its planned pivotal trial, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as “aim,” “anticipate,” "believe," “can,” “continue,” “design,” “estimate,” "expect," "intend," “may,” "plan," “potential,” "will give," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, our ability to submit regulatory filings with the U.S. Food and Drug Administration (FDA) and to obtain and maintain FDA or other regulatory authority approval of our product candidates, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, our competitors’ activities, including decisions as to the timing of competing product launches, pricing and discounting, our integration of an acquired business, which involves a number of risks, including the possibility that the integration process could result in the loss of key employees, the disruption of our ongoing business, or inconsistencies in standards, controls, procedures, or policies, our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire and any unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2022, filed February 28, 2023 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005883/en/

Media

Kevin Giordano

kgiordano@rocketpharma.com

Investors

Brooks Rahmer

investors@rocketpharma.com

Source: Rocket Pharmaceuticals, Inc.

FAQ

What events is Rocket Pharmaceuticals participating in April 2023?

Rocket Pharmaceuticals will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, and Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 25, 2023.

What is the schedule for the Needham Conference related to RCKT?

The Needham Virtual Healthcare Conference presentation by Rocket Pharmaceuticals is on April 18, 2023, at 8:45 a.m. ET.

When does Rocket Pharmaceuticals present at the Chardan Summit?

Rocket Pharmaceuticals will present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 25, 2023, at 9:00 a.m. ET.

Where can I watch Rocket Pharmaceuticals' presentations?

Webcasts of Rocket Pharmaceuticals’ presentations will be available under the 'Events' section of their investor website.

What genetic therapies is RCKT currently developing?

Rocket Pharmaceuticals is developing genetic therapies for Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Danon Disease.